
    
      This study is a multi-center, open-label, Phase 1/2 clinical trial of Radotinib HCl, a
      targeted anticancer agent that inhibits the Bcr-Abl oncoprotein. It is aimed at determining
      the optimal therapeutic dose and confirming safety and efficacy of Radotinib HCl. Phase 1
      study began at St. Mary's hospital in Korea and Phase 2 study is ongoing at 9 Korean sites
      and about 7 sites in China, India and Thailand will take part in Phase 2. After determination
      of a safe and proper therapeutic dose in Phase 1, Phase 2 began continuously to evaluate
      efficacy in chronic and accelerated phases. Before the start of the Phase 2 trial, interim or
      final reports for the Phase 1 trial were reviewed by the Korean Food and Drug Administration.
    
  